Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - December 14, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, is pleased to announce that its management team, including Chief Executive Officer Janet Qi and Chief Scientific Officer Dr. Alan Kozikowski, will be attending the 42nd Annual J.P. Morgan Healthcare Meeting, taking place on January 08-11, 2024, in San Francisco, USA.
This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
PurMinds is set to meet with prospective partners and investors, discussing current and future strategic advancements. This includes showcasing its small molecules (PUR400 series) and non-hallucinogenic Psychedelic molecule (PUR501) clinical programs, and proprietary formulation of botanical Psilocybin program (PUR101) for neurological disorders, as well as showcasing their licensed capacity to produce generic psychedelic compounds and proprietary formulations for worldwide distribution.
If you wish to book a meeting with PurMinds' management team, please contact us by email at ir@purminds.com.
ABOUT PURMINDSTM
PurMinds is a neurological drug development company pursuing breakthrough solutions to neurological and neurodegenerative disorders. Its clinical pipeline includes innovative therapeutics that combine proven mechanisms of action with the powerful ability of psychedelics and other psychoplastogens to rapidly promote neuroplasticity and neuro-rejuvenation, and its drug development program includes the potential for FDA "Breakthrough Designation" with a fast track to Phase IIa. The company's Ontario NeuroLab and Production Facility was granted a Schedule 1 Health Canada Controlled Drugs and Substances Dealer's License authorizing the production, formulation and global supply of pharma-grade Psychedelic compounds including Psilocybin and MDMA for clinical trials and research studies. PurMinds champions a de-risked business model that includes a multi-target approach to drug development, progressing long-term value creation through the accelerated development of novel therapeutics, accompanied by short and mid-term revenue paths. PurMinds is headquartered in Toronto, ON Canada with offices in Boston, MA USA. For further information about PurMinds NeuroPharma, please visit the Company's website at PurMinds.com.
PR Contact
Kristina Spionjak
pr@hlthcommunications.com
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to PurMinds' future business plans and partnerships. Forward-looking statements include words or expressions such as "proposed", "anticipated", "will", "subject to", "near future", "in the event", "would", "expect", "prepared to" and other similar words or expressions and include, but are not limited to: the ability of PurMinds to secure patent protection; the regulatory environment in which PurMinds operates; the ability of PurMinds to carry out its business plans and unforeseen challenges in carrying out such plans; trends in the future use of psychedelics; general business, economic, competitive, political and social uncertainties; the state of capital markets; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/190917
